- Home
- FRME vs CNTA Comparison
FRME vs CNTA Comparison
Compare FRME & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | CNTA |
|---|---|---|
| Founded | 1893 | 2020 |
| Country | United States | United Kingdom |
| Employees | 2086 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 6.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FRME | CNTA |
|---|---|---|
| Price | $41.23 | $39.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $48.33 | $43.17 |
| AVG Volume (30 Days) | 272.4K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $27.67 | N/A |
| Revenue Next Year | $5.91 | N/A |
| P/E Ratio | $10.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.66 | $12.30 |
| 52 Week High | $43.22 | $40.26 |
Technical Indicators
Market Signals| Indicator | FRME | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 63.14 |
| Support Level | $40.84 | $39.36 |
| Resistance Level | $41.66 | $39.90 |
| Average True Range (ATR) | 0.85 | 0.16 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 64.21 | 53.16 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.